Therapy was not safe or tolerable and exacerbated MS resulting in a 3-fold increase in contrast-enhancing lesions, expansion of MBP83-99-specific effector T cell as well as increased intramolecular epitope spreading to disparate epitopes of MBP. This evidence concerns the gene MBP and myeloid sarcoma.